Future Prospects for Pharmacoeconomics and Outcomes Research in the Emerging Regions

Drummond, Michael

doi:10.1016/j.vhri.2013.02.012

Cited by 4 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite novel systemic agents’ promising clinical effectiveness, there is no guarantee that they will be affordable for use within collectively funded healthcare systems. Given that innovations in medicine often impose additional costs when compared to usual care, many healthcare systems around the world now require robust evidence demonstrating that a drug therapy is cost-effective to receive approval for use in clinical practice 57, 58 . As such, it is important to consider the evidence needed to develop a cost-effectiveness analysis when formulating data collection strategies for the evaluation of novel systemic treatments.…”

Section: Cost-effectivenessmentioning

confidence: 99%

Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?

et al. 2019

View full text Add to dashboard Cite

Patients with atopic dermatitis (AD) who do not adequately respond to topical therapy and phototherapy often need systemic immunomodulatory treatment to control their symptoms. Conventional systemic agents, such as ciclosporin, azathioprine, and methotrexate, have been used for decades, but there are concerns about their safety profile. There are now many novel systemic agents emerging through clinical trials, which may have great potential in the treatment of AD. Despite this, there are very few data comparing the performance of these drugs against each other. The purpose of this article is to review the current systemic therapies in AD and present an indirect comparison of systemic AD treatments using effectiveness and safety data from published randomised controlled trials, highlighting important remaining gaps in knowledge. Although the latest developments in systemic AD treatments are exciting and dearly needed, further work is required before the promise of a therapeutic revolution becomes reality.

show abstract

Section: Cost-effectivenessmentioning

confidence: 99%

Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Transferability of outcomes data and epidemiological data is another area of challenge for Asian countries. Drummond [4] hinted at allowing for more exploration of differences in relative treatment effects across regions, countries, and settings. Utilization and cost data are known to be context-specific.…”

mentioning

confidence: 99%